ADVFN US – Market Content Editor
-

Joby Aviation Shares Rise Following New York City Air Taxi Demo Flights
Joby Aviation (NYSE:JOBY) gained 3.8% on Monday after completing the first point-to-point electric vertical takeoff and landing (eVTOL) air taxi demonstration flights in New York City. The company’s aircraft took off from John F. Kennedy International Airport and traveled across the city’s heliport network, including stops at Downtown Skyport as well as the West 30th…
-

Peloton Shares Rise on New Spotify Fitness Collaboration
Peloton Interactive (NASDAQ:PTON) climbed 6% on Monday after Spotify (NYSE:SPOT) revealed a new partnership that brings Peloton fitness content to its platform. Through the collaboration, Spotify Premium subscribers in supported regions will be able to access more than 1,400 ad-free, on-demand classes from Peloton as part of their existing memberships. The offering spans a range…
-

Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans
Sagimet Biosciences Inc. (NASDAQ:SGMT) surged 30% on Monday after unveiling plans to launch a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. during the second half of 2026. The clinical-stage biopharmaceutical company said it is advancing denifanstat into the U.S. acne market, supported by recently reported positive Phase 3…
-

Urban-gro Shifts Focus to Sports Media Following Flash Merger
Urban-gro Inc. (NASDAQ:UGRO) has announced a strategic pivot away from its roots in controlled environment agriculture, repositioning itself as a sports, media, and experiential marketing platform after merging with Flash Sports & Media Inc.. The company finalized its acquisition of Flash on February 17, 2026, after first revealing the deal on October 14, 2025. With…
-

WW International Targets Debt Reduction with Up to $40 Million Prepayment
WW International Inc. (NASDAQ:WW) said it intends to allocate as much as $40 million in cash toward reducing the principal balance of its outstanding term loan, according to a company statement. The planned repayment includes two parts: between $25 million and $30 million to cover the annual cash sweep payment due on June 24, 2026,…
-

Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations
Fulcrum Therapeutics Inc. (NASDAQ:FULC) moved higher in pre-market trading on Monday after reporting first-quarter results that topped analyst expectations. The clinical-stage biopharmaceutical firm posted a loss of $0.25 per share for the quarter, coming in ahead of forecasts calling for a $0.30 per share loss. Net loss totaled $18.9 million for the three months ended…
-

Lakeland Financial Tops EPS Estimates but Misses on Revenue
Lakeland Financial Corporation (NASDAQ:LKFN) reported first-quarter results on Monday that exceeded earnings expectations but came in slightly below revenue forecasts. Adjusted earnings per share were $1.04, beating the analyst consensus of $1.01 by $0.03, while revenue totaled $69.71 million, missing estimates of $70.42 million. The stock remained unchanged in after-hours trading following the release. Net…
-

Veradermics Shares Jump 17% on Promising Hair Loss Trial Results
Veradermics Incorporated (NYSE:MANE) saw its stock rise 17% on Monday after announcing positive topline data from a Phase 2/3 clinical study of its oral hair loss treatment, VDPHL01. The trial, known as Study ’302’, included 519 participants and successfully met all primary and key secondary endpoints with statistical significance. VDPHL01, an extended-release formulation of minoxidil,…
-

HBT Financial Tops Forecasts as CNB Acquisition Lifts Performance
HBT Financial Inc. (NASDAQ:HBT) reported first-quarter results on Monday that exceeded expectations, supported by the recent acquisition of CNB Bank Shares, with the stock rising 2.10% in pre-market trading. Adjusted earnings per share came in at $0.68, ahead of analyst forecasts of $0.62, while revenue reached $67.33 million, surpassing estimates of $66.75 million. The company…
-

Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results
Oruka Therapeutics Inc. (NASDAQ:ORKA) saw its shares surge 45% after releasing encouraging Week 16 data from its ongoing EVERLAST-A Phase 2a study in patients with moderate-to-severe plaque psoriasis. The trial met its primary objective, with 63.5% of patients treated with ORKA-001 achieving PASI 100 at Week 16, indicating complete skin clearance. An identical proportion also…